Search the Newsreel

Talanx erhöht Prognose vor Hurrikan-Saison

Telix Pharmaceuticals (TLX) to Release Quarterly Earnings on Thursday

Telix Pharmaceuticals (ASX:TLX) Posts US$247M Quarter and Targets Over US$1B 2026 Revenue Plus Other Income

Telix Pharmaceuticals reported its strongest quarterly revenue to date, reaching US$247 million in Q2 2026, driven by its Precision Medicine division. The company projects its total 2026 revenue plus other income to exceed US$1 billion, bolstered by a US$40 million payment from a new …

Telix Pharmaceuticals Stock Leads This ASX Growth Screen With Strong Insider Backing

Telix Stock Price Weakness Could Be Hiding A Growth Story

This article highlights three growth stocks with high insider ownership: Predictive Discovery (ASX:PDI), Telix Pharmaceuticals (ASX:TLX), and Lindian Resources (ASX:LIN). It discusses their current financial situations, growth prospects, and associated risks, suggesting they are candidates for further investor research. The piece emphasizes looking for …

Investor Alert: Deadline Approaching to Join Telix Pharmaceuticals Ltd. (TLX) Class Action - Contact Levi & Korsinsky

Levi & Korsinsky, LLP has announced a securities class action lawsuit against Telix Pharmaceuticals Ltd. (NASDAQ: TLX) on behalf of investors who purchased securities between February 21, 2025, and August 28, 2025. The lawsuit alleges that Telix Pharmaceuticals made false and misleading statements regarding …

Telix Pharmaceuticals Limited (NASDAQ:TLX) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Telix Pharmaceuticals Limited (NASDAQ:TLX) has received a "Moderate Buy" consensus recommendation from analysts, with an average 12-month price target of $20.40. The stock recently traded up 8.3% at $11.52, remaining above its 50-day and 200-day moving averages. Institutional investors have also increased their positions …

Telix to Host R&D Day in New York City on September 22, 2026

Telix Pharmaceuticals Limited will host an R&D Day in New York City on September 22, 2026, for institutional investors and analysts, providing an overview of its therapeutic and precision medicine pipeline. The event will feature presentations from Telix's leadership and key opinion leaders. Additionally, …

Telix R&D Day to Feature Pipeline Updates and Outside Experts

Telix Pharmaceuticals (ASX: TLX, NASDAQ: TLX) will host an in-person Research and Development Day in New York City on September 22, 2026, for institutional investors and analysts to discuss its therapeutic and precision medicine pipeline. The event will feature presentations from senior leadership and …

Class Action Alert: Levi & Korsinsky Reminds Telix Pharmaceuticals Ltd. (TLX) Investors of January 9, 2026 Deadline

Levi & Korsinsky, LLP has announced a securities class action lawsuit against Telix Pharmaceuticals Ltd. (NASDAQ: TLX) on behalf of investors who purchased securities between February 21, 2025, and August 28, 2025. The lawsuit alleges that Telix Pharmaceuticals made false and misleading statements regarding …

How Investors May Respond To Telix Pharmaceuticals (ASX:TLX) Upgraded FY26 Guidance And Pipeline Milestones

Telix Pharmaceuticals: The Radiopharma Operating System Is The Real Moat (NASDAQ:TLX)

Telix Schedules Aug. 20 Webcast for Half-Year Results

Telix Pharmaceuticals will release its financial results for the half-year ended June 30, 2026, on Thursday, August 20, 2026. An investor webcast and conference call are scheduled for 9:00 a.m. AEST on that day (7:00 p.m. EDT on Wednesday, August 19, 2026). The company, …

Telix Pharmaceuticals Stock And 2 Fast Growing Insider Owned ASX Shares

This article highlights three fast-growing ASX companies with high insider ownership: Predictive Discovery (ASX:PDI), Telix Pharmaceuticals (ASX:TLX), and Lindian Resources (ASX:LIN). It discusses their financial outlooks, market positions, and the risks involved, emphasizing that high insider ownership can align company decisions with investor interests. …

Telix Pharmaceuticals to release H1 2026 financial results on August 20 with investor webcast.

Telix Pharmaceuticals announced it would release its financial results for the half-year ended June 30, 2026, on August 20, 2026. The company, a global radiopharmaceutical firm focused on cancer theranostics, will also hold an investor webcast and conference call on the same day to …

Short Interest in Telix Pharmaceuticals Limited (NASDAQ:TLX) Increases By 82.7%

Short interest in Telix Pharmaceuticals Limited (NASDAQ:TLX) saw a substantial increase of 82.7% by July 15th, reaching 297,140 shares. This represents approximately 0.1% of the company's outstanding shares, with a short-interest ratio of 1.8 days. Despite mixed analyst ratings and some downgrades, several institutional …

Telix Pharmaceuticals Ltd (TLX) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Telix Pharmaceuticals Ltd (TLX), detailing various indicators and moving averages. It summarizes the signals from technical indicators as "Neutral" and offers insights into buy/sell signals based on different moving averages. The analysis is presented as a reference …

Equities Analysts Set Expectations for TLX FY2026 Earnings

HC Wainwright has lowered its FY2026 earnings estimate for Telix Pharmaceuticals to $0.07 per share from $0.15, while maintaining a "Buy" rating and a $20 price target. This revised estimate is slightly above the $0.06 consensus forecast. Telix Pharmaceuticals (NASDAQ:TLX) currently holds a consensus …

Telix Pharmaceuticals Limited Revenue Breakdown – BOATS:TLX

Telix Pharmaceuticals Limited (TLX) generated 803.80 million USD in revenue last year, with its Precision Medicine segment contributing the most at 621.93 million USD. The United States was the largest regional contributor, accounting for 784.90 million USD of the total revenue. This highlights the …

Telix Pharmaceuticals Ltd (TLX) Balance Sheet

This article provides access to the annual and quarterly balance sheets for Telix Pharmaceuticals Ltd (TLX) to help investors evaluate the company's financial health, analyze fundamentals, and calculate key financial ratios. It also includes an FAQ section detailing important balance sheet metrics, the differences …

TLX|Telix Pharmaceuticals Ltd|Price:12.310|Chg%:+0.340

Telix Pharmaceuticals Ltd (TLX) Institutional Confidence

This article focuses on the institutional confidence in Telix Pharmaceuticals Ltd (TLX), displaying recent shareholder activity. It lists several investment firms, including Portland Investment Counsel Inc. and Lazard Asset Management, L.L.C., along with their current shares held and the percentage change in their holdings. …

Telix Pharmaceuticals Ltd. (TLX) Class Action Lawsuit: Levi & Korsinsky Reminds Investors of January 9, 2026 Deadline

Levi & Korsinsky, LLP has filed a securities class action lawsuit against Telix Pharmaceuticals Ltd. (NASDAQ: TLX) on behalf of investors who purchased securities between February 21, 2025, and August 28, 2025. The lawsuit alleges that Telix Pharmaceuticals made false and misleading statements regarding …

Telix Q2 Revenue US$247M, Strong Momentum and Pipeline Progress

Telix Pharmaceuticals Limited reported Q2 2026 group revenue of US$247 million, a 7% increase quarter-over-quarter and 21% year-over-year, driven by strong growth in its Precision Medicine segment. The company expects full-year 2026 revenue to exceed US$1 billion and has updated its R&D expenditure guidance …

What Telix Pharmaceuticals (ASX:TLX)'s Upgraded US$1 Billion FY26 Outlook Means For Shareholders

Telix Pharmaceuticals (ASX:TLX) recently reported positive clinical data, initiated a Phase 3 trial, and raised its FY26 revenue outlook to over US$1 billion. These developments signify strong progress in its radiopharmaceutical pipeline and validate its theranostic business model. The upgraded guidance reinforces the company's …

Telix Pharmaceuticals (TLX) Gains Ground: Approaching Key Resistance at $11.04 - Mean Reversion Trade

Telix Pharmaceuticals (TLX) Status Update Summary

Telix Pharmaceuticals provided a status update on its urology therapeutic strategy and pipeline, focusing on prostate, kidney, and bladder cancers. The company highlighted its comprehensive portfolio, including lead asset TLX591 in phase III for prostate cancer, and next-generation therapies. Telix also discussed its kidney …

Does Telix Pharmaceuticals Limited (TLX) Have the Potential to Rally 86.17% as Wall Street Analysts Expect?

Study Tests Imaging to Select Patients for Telix Prostate Therapy

Telix Pharmaceuticals announced the publication of results from its Phase 1 ProstACT SELECT study in the journal Cancers. The study evaluated the use of 68Ga-PSMA-PET imaging to select patients for TLX591-Tx, a PSMA-targeting radio antibody-drug conjugate for advanced metastatic castration-resistant prostate cancer (mCRPC). The …

TLX591-Tx ProstACT SELECT Study Published in Cancers Journal

Telix Pharmaceuticals announced the publication of results from its ProstACT SELECT study in Cancers journal. The study confirmed the utility of 68Ga (gallium)-PSMA-PET imaging for selecting patients for TLX591-Tx therapy, a PSMA-targeting rADC therapy candidate for advanced metastatic prostate cancer. Results highlighted the therapy's …

Telix Pharmaceuticals (TLX) hits US$247M Q2, inks Regeneron deal

Telix Pharmaceuticals reported strong Q2 2026 revenue of US$247 million, a 21% year-over-year increase, with Precision Medicine revenue up 30%. The company expects FY 2026 revenue to exceed US$1 billion and has increased its R&D spending guidance to accelerate late-stage programs. Telix also announced …

Telix Pharmaceuticals: Q2 2026 revenue jumps 21%

Telix Pharmaceuticals (TLX) Q2 2026 TU earnings summary

Telix Pharmaceuticals (TLX) reported Q2 2026 group revenue of US $247 million, a 21% year-over-year increase, with Precision Medicine revenue up 30% YoY. The company reached FDA alignment for its ProstACT Global Phase 3 study and initiated a strategic collaboration with Regeneron, receiving a …